{"title":"Behavioral and histopathological insights into phenylthiazolyl-1,3,5-triazines: potential antidepressant candidates in a rat model of depression.","authors":"Aarti Sati, Pynshngainlang Kyllait, Prashant Gahtori, Hans Raj Bhat, Md Sadique Hussain, Gaurav Gupta, Archana Gahtori","doi":"10.1515/jcim-2024-0417","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the antidepressant-like effects of Phenylthiazolyl-1,3,5-triazine derivatives through behavioral tests, molecular docking, and histopathological analysis in a rat brain model of depression.</p><p><strong>Methods: </strong>Phenylthiazolyl-1,3,5-triazine derivatives were synthesized and administered at a dose of 30 mg/kg in albino rats. Behavioral effects were assessed using the Forced Swim Test and Tail Suspension Test. Molecular docking with MD simulations via CDocker was employed to analyze ligand-receptor interactions. Histological analysis of brain tissues was conducted to assess structural and vascular changes.</p><p><strong>Results: </strong>Among the derivatives, PS1 and PS5 showed significant antidepressant-like activity compared to standard imipramine. Molecular docking revealed that hydrogen bonding, pi-pi interactions, and intermolecular neighbor effects stabilized the ligand-receptor complexes. Histopathological analysis of PS1-treated rats demonstrated preserved vascular integrity, reduced edema, and the absence of hydrophobic alterations.</p><p><strong>Conclusions: </strong>Phenylthiazolyl-1,3,5-triazines, particularly PS1, exhibit promising potential as antidepressant agents. Their behavioral efficacy and protective histological effects suggest therapeutic relevance. Further studies integrating biomarkers and gene expression analyses are needed to optimize these derivatives for clinical application.</p>","PeriodicalId":15556,"journal":{"name":"Journal of Complementary and Integrative Medicine","volume":" ","pages":"270-278"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Complementary and Integrative Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/jcim-2024-0417","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: To evaluate the antidepressant-like effects of Phenylthiazolyl-1,3,5-triazine derivatives through behavioral tests, molecular docking, and histopathological analysis in a rat brain model of depression.
Methods: Phenylthiazolyl-1,3,5-triazine derivatives were synthesized and administered at a dose of 30 mg/kg in albino rats. Behavioral effects were assessed using the Forced Swim Test and Tail Suspension Test. Molecular docking with MD simulations via CDocker was employed to analyze ligand-receptor interactions. Histological analysis of brain tissues was conducted to assess structural and vascular changes.
Results: Among the derivatives, PS1 and PS5 showed significant antidepressant-like activity compared to standard imipramine. Molecular docking revealed that hydrogen bonding, pi-pi interactions, and intermolecular neighbor effects stabilized the ligand-receptor complexes. Histopathological analysis of PS1-treated rats demonstrated preserved vascular integrity, reduced edema, and the absence of hydrophobic alterations.
Conclusions: Phenylthiazolyl-1,3,5-triazines, particularly PS1, exhibit promising potential as antidepressant agents. Their behavioral efficacy and protective histological effects suggest therapeutic relevance. Further studies integrating biomarkers and gene expression analyses are needed to optimize these derivatives for clinical application.
期刊介绍:
Journal of Complementary and Integrative Medicine (JCIM) focuses on evidence concerning the efficacy and safety of complementary medical (CM) whole systems, practices, interventions and natural health products, including herbal and traditional medicines. The journal is edited by Ed Lui of the University of Western Ontario. Topics: -Quality, efficacy, and safety of natural health products, dietary supplements, traditional medicines and their synthetic duplicates -Efficacy and safety of complementary therapies -Evidence-based medicine and practice, including evidence of traditional use -Curriculum development, educational system and competency of complementary health programs -Methodologies on research and evaluation of traditional medicines and herbal products -Integrative medicine: basic and clinical research and practice -Innovation in CAM Curriculum -Educational Material Design